Aberdeen Group
KNSA icon

Aberdeen Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Aberdeen Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Sell
373,634
-26,964
-7% -$1.19M 0.03% 454
2025
Q4 		$16.5M Buy
400,598
+241,876
+152% +$9.7M 0.03% 491
2025
Q3 		$6.16M Buy
+158,722
New +$5.16M 0.01% 677

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Aberdeen Group's KNSA Position: Q1 2026 in Review

Aberdeen Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 6.7% in Q1 2026, selling an estimated $1.19M and leaving 373,634 shares worth $18M. The position accounts for 0.03% of the portfolio, ranked #454.

Aberdeen Group first reported a position in KNSA in Q3 2025 and has held it in 3 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Aberdeen Group held 373,634 shares of Kiniksa Pharmaceuticals worth $18M as of Q1 2026.
  • Aberdeen Group sold 26,964 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $1.19M.
  • Kiniksa Pharmaceuticals made up 0.03% of Aberdeen Group's portfolio in Q1 2026, its #454 holding.
  • Aberdeen Group first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.